Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueEBIATGross ProfitShares OutstandingShares Outstanding
Ratios

Goldenwell Biotech (GWLL) Gross Profit (2021 - 2025)

Goldenwell Biotech filings provide 5 years of Gross Profit readings, the most recent being $25000.0 for Q3 2025.

  • On a quarterly basis, Gross Profit changed N/A to $25000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $62415.0, a 43546.85% increase, with the full-year FY2024 number at $64.0, down 90.39% from a year prior.
  • Gross Profit hit $25000.0 in Q3 2025 for Goldenwell Biotech, down from $37500.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $37500.0 in Q2 2025 to a low of -$85.0 in Q4 2024.
  • Median Gross Profit over the past 5 years was $646.0 (2021), compared with a mean of $7023.6.
  • Biggest five-year swings in Gross Profit: tumbled 216.44% in 2024 and later soared 53471.43% in 2025.
  • Goldenwell Biotech's Gross Profit stood at $2578.0 in 2021, then surged by 793.25% to $23028.0 in 2022, then plummeted by 99.68% to $73.0 in 2023, then tumbled by 216.44% to -$85.0 in 2024, then skyrocketed by 29511.76% to $25000.0 in 2025.
  • The last three reported values for Gross Profit were $25000.0 (Q3 2025), $37500.0 (Q2 2025), and -$85.0 (Q4 2024) per Business Quant data.